下一步，佛山市市场监督管理局将严格按照省级主管部门的部署和要求，加强对指定医疗机构的指导管 理。重点围绕港澳药械的购进验收、储存保管条件、制度建设、应急处置及风险防范等方面进行检查， 督促各机构切实落实主体责任，建立健全涵盖申请、采购、储存、使用、追溯及风险管控的全链条管理 制度，实现药械来源可溯、去向可追、风险可控、责任可究。（来源：佛山市市场监督管理局网站） 中国质量新闻网讯 近日，广东省卫生健康委员会、广东省药品监督管理局联合印发通知，公布了粤港 澳大湾区"港澳药械通"第四批指定医疗机构名单。此次新增的27家机构中，佛山市共有5家医疗机构入 选，包括佛山市第一人民医院、南方医科大学第八附属医院（佛山市顺德区第一人民医院）、佛山市南 海区人民医院（华南理工大学附属第六医院）、广东省人民医院南海医院、和祐至臻医院。此前，佛山 复星禅诚医院已纳入该名单。至此，佛山市"港澳药械通"指定医疗机构已达6家。这标志着"港澳药械 通"政策在佛山市的落地实施得到进一步拓展，将为佛山市民使用国际先进药品和医疗器械开辟更便捷 的通道，助力佛山市医药行业高质量发展。 "港澳药械通"政策是国家支持粤港澳大湾区建设的重大创新举措， ...

"有微骨折的、有自体软骨截骨移植的，我自己也在网上查询相关的治疗方式，一直想找一种创伤小， 效果又比较好的治疗方式。"姚先生说。2026年1月。姚先生从复旦大学附属华山医院（以下简称"华山 医院"）运动医学科听到了一个令他振奋的好消息：通过"港澳药械通"政策，北大深圳医院引进了一项 微创软骨修复手术，这是目前唯一不用联合微骨折的软骨再生技术。 上海男子踝关节软骨损伤 "港澳药械通"破解难题 据悉，复旦大学附属华山医院运动医学科陈世益教授团队，是北大深圳医院通过深圳市医疗卫生"三名 工程"引进的高层次医学团队，双方自2016年开展合作以来，在运动医学的医、教、研等领域开展深度 合作。在该团队帮助下，北大深圳医院运动医学科已发展成为国家临床重点学科、深圳市运动医学质量 控制中心。经过综合考虑，姚先生决定前往深圳寻求新的治疗方式。 5分钟构建软骨再生支架 患者有望恢复运动功能 关节软骨损伤了，无需做软骨移植，就能让软骨再生？日前，依托"港澳药械通"政策支持，北京大学深 圳医院（以下简称"北大深圳医院"）成功完成深圳首批软骨再生胶原蛋白填充支架ChondroFiller liquid （简称CF）手术，为3名饱受关节 ...

辉瑞制药高级副总裁钱云建议，广东可借助先发优势，率先建设"省级商保创新药结算平台"，彻底告 别"先垫付、后理赔"，同时统一标准以降低保险公司运营成本，形成"目录—支付—使用"的良性循环。 强生创新制药中国区总裁黄琛则建议出台具体激励措施，鼓励医疗机构加快落地商保，并加强国谈药落 地政策的培训宣传，让好政策真正穿透至医生层面。 1月28日，2026跨国药企大湾区行座谈会在广州举行。来自强生、辉瑞、阿斯利康、拜耳等15家跨国药 企的40余位中国区总裁及部门负责人，广东省有关单位和珠三角九市政府相关负责人和专家齐聚一堂， 一场汇聚全球医药产业顶尖智慧的对话在此展开。 各方围绕"国家医保谈判药物在大湾区落地""创新药商业健康保险进展""'港澳药械通'实施与优化"等话 题进行深入交流，展现大湾区吸引全球医药创新资源的决心，勾勒出构建开放共赢产业生态的路径。 政企共探医药高质量发展"湾区方案" 座谈会上，广东省相关部门负责人介绍，近两年来，广东密集出台了近20份相关政策文件，形成覆盖全 产业链的发展规划、针对优势领域的专项政策及布局未来产业的行动方案"组合拳"，旨在为企业打造全 方位、可持续的优良发展环境。 与会跨国药企 ...

Core Insights - The gathering of over 40 executives from 15 multinational pharmaceutical companies in the Greater Bay Area (GBA) highlights the region's growing importance in the biopharmaceutical industry [1][3] - The event serves as a platform for dialogue between government and industry leaders to explore the GBA's advantages and future potential in biopharmaceutical development [1][3] Group 1: Investment and Development - Multinational pharmaceutical companies are increasingly establishing production bases and regional headquarters in the GBA, signaling strong confidence in the region's biopharmaceutical industry [3][4] - The GBA has been recognized for its favorable business environment, with Guangdong province leading in foreign investment and being rated as having the best business environment in China [4][6] Group 2: Market Potential and Resources - Guangdong's healthcare market is vast, with a basic medical insurance enrollment of 112 million people by the end of 2024, and it leads the nation in the scale of pharmaceutical circulation and the number of top-tier hospitals [4][9] - The integration of the Guangdong-Hong Kong-Macao markets is unlocking significant potential in the biopharmaceutical sector, with a focus on translating advantages into patient benefits [6][12] Group 3: Regulatory and Collaborative Framework - The "Hong Kong-Macao Drug and Medical Device Access" initiative has facilitated the approval of 149 drug and medical device varieties, enhancing patient access to innovative treatments [7][8] - The establishment of a provincial commercial health insurance platform aims to alleviate patient financial burdens, further promoting the use of innovative drugs [8][9] Group 4: Innovation and Research - The GBA is becoming a key innovation hub, with one-third of global biopharmaceutical research pipelines originating from China, and many multinational companies are shifting early-stage research to the region [9][11] - The region has seen a significant increase in the approval of innovative drugs and medical devices, with a 667% increase in first-class innovative drugs approved during the 14th Five-Year Plan compared to the previous period [9][10] Group 5: Future Directions and Challenges - The collaboration between Guangdong and Hong Kong is crucial for enhancing the accessibility of innovative drugs, with a focus on real-world data and joint research initiatives [12][16] - Challenges such as cross-border regulation, data flow, and talent mobility need to be addressed to optimize the biopharmaceutical industry's collaborative efforts in the GBA [16][17]

Group 1 - The core viewpoint of the article highlights Shenzhen's economic growth, with a projected 14.4% year-on-year increase in actual foreign investment by 2025, and the city maintaining the top position in both industrial output and added value for four consecutive years [1] - Shenzhen's total import and export volume is expected to reach 4.55 trillion yuan by 2025, continuing its lead among Chinese cities for two consecutive years [1] - High-tech product exports, including new energy vehicles, consumer drones, digital cameras, and 3D printers, are projected to grow by 10.1% year-on-year [1] Group 2 - Shenzhen plans to enhance cooperation with APEC member economies and expand its international network of friendly relations with innovative cities and important ports [1] - The "Bay Area Pass" project will be implemented, with significant infrastructure developments such as the reconstruction of the Shatoujiao port and the renovation of the Luohu port, leading to a 14.0% year-on-year increase in passenger traffic at land ports with Hong Kong [1] - Shenzhen will issue offshore RMB local government bonds totaling 5 billion yuan, marking its first issuance in Macau and the fifth consecutive year in Hong Kong, with a 65.6% year-on-year increase in "Shenzhen-Hong Kong Stock Connect" trading volume [1]

Core Insights - The inclusion of Longgang District Ear, Nose, and Throat Hospital in the "Hong Kong-Macao Medical Device Pass" program marks a significant step in enhancing specialized medical services in the Guangdong-Hong Kong-Macao Greater Bay Area [1][2] - The "Hong Kong-Macao Medical Device Pass" initiative aims to facilitate the introduction of innovative drugs and medical devices that are urgently needed in clinical settings, benefiting local patients without the need for cross-border travel [1] Group 1 - Longgang District Ear, Nose, and Throat Hospital is now one of the seven newly designated medical institutions in Shenzhen, and the only tertiary public ENT specialty hospital in the Greater Bay Area to receive this qualification [1] - The policy has allowed the introduction of over 140 types of medical devices and drugs since its pilot launch in 2021, benefiting approximately 17,000 patients [1] - The initiative provides a platform for residents to access cutting-edge ENT, dental, and ophthalmological services locally, addressing the urgent demand for advanced medical solutions, especially for rare and complex diseases [1] Group 2 - The hospital plans to establish a comprehensive management system for the "Hong Kong-Macao Medical Device Pass," focusing on the clinical needs for medications and devices [2] - As the only ENT specialty hospital in the Greater Bay Area, it aims to develop seven specialized centers, including those for skull base surgery, sleep medicine, vestibular medicine, allergy, comfortable treatment, dental care, and ophthalmology [2] - The introduction of these medical devices will fill clinical gaps in complex hearing reconstruction, minimally invasive surgery for skull base tumors, and interventions for refractory allergic diseases, significantly enhancing the hospital's specialized treatment capabilities [2]

Core Viewpoint - The inclusion of Guangzhou Taihe Cancer Hospital in the "Hong Kong-Macao Drug and Device Pass" list represents a significant breakthrough for the company in accessing international medical resources and enhancing its service capabilities in cancer treatment [1][2]. Group 1: Company Developments - The hospital has successfully passed the approval process to be listed as a designated medical institution under the "Hong Kong-Macao Drug and Device Pass" policy, which facilitates the introduction of innovative drugs and devices approved in Hong Kong and Macao but not yet available in mainland China [1]. - This policy is expected to broaden the legal supply channels for urgently needed clinical treatments, providing policy support for residents in the Greater Bay Area to access advanced medical services in line with international standards [1][2]. - The company has established professional barriers in precision treatment, proton therapy, and multidisciplinary diagnosis and treatment, which will be further strengthened by this new designation [1][3]. Group 2: Industry Implications - The advancement of the "Hong Kong-Macao Drug and Device Pass" not only enhances the service capabilities of individual institutions but also contributes to the construction of a high-level medical service network characterized by tiered diagnosis and regional collaboration [2]. - Designated medical institutions can attract patients from surrounding areas by introducing international innovative drugs and devices, gradually forming regional cancer treatment centers and optimizing the allocation of medical resources [2]. - The ongoing release of policy dividends in the Greater Bay Area is expected to accelerate the flow of cross-border medical resources, allowing the company to benefit continuously from its specialized and international strategic layout [2].

Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, positioning itself as a key beneficiary of the policy and providing clear growth opportunities for investors [1][3]. Group 1: Company Developments - The approval allows Guangzhou Taihe Tumor Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1]. - The hospital can now introduce innovative drugs and medical devices in the oncology field, enhancing its competitive advantage and broadening its business scope [1][2]. Group 2: Industry Implications - The "Hong Kong-Macao Drug and Medical Device Access" initiative aims to improve the quality of medical services and align domestic treatments with international standards, particularly in oncology [2][3]. - The initiative is expected to reduce the treatment time gap between mainland China and international markets, particularly for diseases like breast cancer and lung cancer, thereby enhancing patient treatment options [2]. - The increased accessibility of cross-border medical resources will likely attract more patients to hospitals with such capabilities, creating a "regional treatment center" effect and increasing overall service intensity [2][3].

Core Viewpoint - The Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration have issued a notice regarding the fourth batch of designated medical institutions under the "Hong Kong-Macao Medical Device and Drug Access" initiative, adding 27 new hospitals while removing one [1] Group 1: Designated Medical Institutions - The new designated hospitals include 27 medical institutions such as the Southern Medical University Zhujiang Hospital, while the Foshan Ximalin Shunchao Eye Hospital has been removed from the list [1] - The application process for the fourth batch of designated medical institutions began in August, with a review of the qualifications of the previous three batches [1] - A total of 44 hospitals passed the qualification review, and the current total of designated medical institutions has reached 71 [1] Group 2: Regulatory and Operational Requirements - The notice mandates that relevant municipal administrative departments enhance supervision and management of designated medical institutions [1] - Designated medical institutions are required to deepen cooperation with Hong Kong and Macao in medical services, clinical research, and the importation of medical devices and drugs [1] - The initiative aims to ensure that imported Hong Kong and Macao medical devices and drugs are used solely for specific medical purposes within the institutions, ensuring safety in medication and equipment [1] Group 3: Historical Context and Impact - The "Hong Kong-Macao Medical Device and Drug Access" initiative was officially implemented in Guangdong Province in 2021, with three previous batches of designated institutions announced in August 2021, February 2023, and September 2024 [1] - A total of 140 varieties of drugs and medical devices (63 drugs and 77 devices) have been approved for import and use, benefiting approximately 17,000 patients [1]

Core Viewpoint - The stock of Meizhong Jiahe (02453) opened over 6% higher following the approval of its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Pass" designated medical institution list [1] Group 1: Company Developments - Meizhong Jiahe's stock rose by 6.12%, reaching HKD 2.08, with a trading volume of HKD 100,700 [1] - The approval allows Guangzhou Taihe Oncology Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, enhancing its competitive advantage in the oncology field [1] Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Pass" is a key initiative under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] - Designated medical institutions in the Greater Bay Area can leverage special pharmaceutical policies, allowing them to access advanced medical solutions [1] - The initiative aims to broaden the business scope of qualified institutions and provide urgently needed medications to more oncology patients, thereby strengthening the overall competitive landscape in the oncology medical sector [1]